Natriuretic peptides: Novel therapeutic targets in heart failure

Alessandro Cataliotti, John C Jr. Burnett

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Since the discovery of the cardiac hormone atrial natriuretic peptide by de Bold and colleagues in 1981, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure. This new knowledge builds on the importance of cardiorenal mechanisms that contribute to optimal cardiovascular regulation. Recent investigations by our group and others have also established the direct myocardial actions of the natriuretic peptides, broadening their therapeutic potential beyond renal mechanisms. Indeed, a potential therapeutic target is cardiac remodeling and fibrosis based on the unique cardiorenal and humoral protective properties that natriuretic peptides possess. We review new insights into the natriuretic peptide system and specifically focus on the possible role of natriuretic peptides as a new therapeutic strategy to limit cardiac remodeling and fibrosis to delay worsening of cardiac function and the progression of heart failure.

Original languageEnglish (US)
Pages (from-to)378-384
Number of pages7
JournalJournal of Investigative Medicine
Volume53
Issue number7
StatePublished - Nov 2005

Fingerprint

Natriuretic Peptides
Heart Failure
Fibrosis
Therapeutics
Translational Medical Research
Atrial Natriuretic Factor
Hormones
Kidney

Keywords

  • Aldosterone
  • Atrial natriuretic peptide
  • Brain natriuretic peptide
  • Particulate guanylate cyclase

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Natriuretic peptides : Novel therapeutic targets in heart failure. / Cataliotti, Alessandro; Burnett, John C Jr.

In: Journal of Investigative Medicine, Vol. 53, No. 7, 11.2005, p. 378-384.

Research output: Contribution to journalArticle

@article{dae542db00e440f3bc2592426303ce12,
title = "Natriuretic peptides: Novel therapeutic targets in heart failure",
abstract = "Since the discovery of the cardiac hormone atrial natriuretic peptide by de Bold and colleagues in 1981, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure. This new knowledge builds on the importance of cardiorenal mechanisms that contribute to optimal cardiovascular regulation. Recent investigations by our group and others have also established the direct myocardial actions of the natriuretic peptides, broadening their therapeutic potential beyond renal mechanisms. Indeed, a potential therapeutic target is cardiac remodeling and fibrosis based on the unique cardiorenal and humoral protective properties that natriuretic peptides possess. We review new insights into the natriuretic peptide system and specifically focus on the possible role of natriuretic peptides as a new therapeutic strategy to limit cardiac remodeling and fibrosis to delay worsening of cardiac function and the progression of heart failure.",
keywords = "Aldosterone, Atrial natriuretic peptide, Brain natriuretic peptide, Particulate guanylate cyclase",
author = "Alessandro Cataliotti and Burnett, {John C Jr.}",
year = "2005",
month = "11",
language = "English (US)",
volume = "53",
pages = "378--384",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Natriuretic peptides

T2 - Novel therapeutic targets in heart failure

AU - Cataliotti, Alessandro

AU - Burnett, John C Jr.

PY - 2005/11

Y1 - 2005/11

N2 - Since the discovery of the cardiac hormone atrial natriuretic peptide by de Bold and colleagues in 1981, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure. This new knowledge builds on the importance of cardiorenal mechanisms that contribute to optimal cardiovascular regulation. Recent investigations by our group and others have also established the direct myocardial actions of the natriuretic peptides, broadening their therapeutic potential beyond renal mechanisms. Indeed, a potential therapeutic target is cardiac remodeling and fibrosis based on the unique cardiorenal and humoral protective properties that natriuretic peptides possess. We review new insights into the natriuretic peptide system and specifically focus on the possible role of natriuretic peptides as a new therapeutic strategy to limit cardiac remodeling and fibrosis to delay worsening of cardiac function and the progression of heart failure.

AB - Since the discovery of the cardiac hormone atrial natriuretic peptide by de Bold and colleagues in 1981, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure. This new knowledge builds on the importance of cardiorenal mechanisms that contribute to optimal cardiovascular regulation. Recent investigations by our group and others have also established the direct myocardial actions of the natriuretic peptides, broadening their therapeutic potential beyond renal mechanisms. Indeed, a potential therapeutic target is cardiac remodeling and fibrosis based on the unique cardiorenal and humoral protective properties that natriuretic peptides possess. We review new insights into the natriuretic peptide system and specifically focus on the possible role of natriuretic peptides as a new therapeutic strategy to limit cardiac remodeling and fibrosis to delay worsening of cardiac function and the progression of heart failure.

KW - Aldosterone

KW - Atrial natriuretic peptide

KW - Brain natriuretic peptide

KW - Particulate guanylate cyclase

UR - http://www.scopus.com/inward/record.url?scp=29144468019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144468019&partnerID=8YFLogxK

M3 - Article

C2 - 16297366

AN - SCOPUS:29144468019

VL - 53

SP - 378

EP - 384

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 7

ER -